Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Anne Daub

Anne Daub is a Partner on the Therapeutics team, and joined the Firm in 2024. Prior to Deerfield, Ms. Daub was a Vice President and Biotechnology Senior Analyst for T. Rowe Price for more than five years. Before this, she was a Senior Analyst at Soros Fund Management LLC and Citadel LLC. Prior to these roles, Ms. Daub was an Analyst at Visium Asset Management for eight years and also held positions at Bear Stearns & Co., Integrated Finance Ltd. and J.P. Morgan Securities Inc. She holds a graduate degree in Finance from H.E.C Graduate School of Management in Paris, France.  

Victoria (Tori) Fleek

Victoria (Tori) Fleek is a Corporate Development Analyst. Ms. Fleek joined the Firm in 2022 as a Business Development intern.  Prior to Deerfield, Ms. Fleek spent more than six years at PwC in roles of increasing responsibility, including most recently as Senior Manager, Consulting – Pharmaceutical & Life Sciences R&D Services. Ms. Fleek holds a B.A.Sc. in Bioengineering and Biomedical Engineering from Worcester Polytechnic Institute and an M.B.A. from the NYU Stern School of Business.

Cody Parks

Cody Parks is a Trade Operations Associate and joined the Firm in 2023. Prior to Deerfield, Mr. Parks was a Derivatives Trade Management Analyst at Credit Suisse for more than two years. He holds a B.S. in Finance and Risk Management from the University of Southern Maine. 

Moses Adubi

Moses Adubi is a Principal on the Healthcare Services team and joined the Firm in 2023. Prior to Deerfield, Mr. Adubi was a Healthcare Investor on the Venture Capital Investment Team at Optum Ventures for more than two years. Before Optum, he spent more than five years at Morgan Stanley, first as an Associate in the Private Wealth Management Global Rotational Program and then as an Analyst on the Global Technology Investment Banking Team. Mr. Adubi holds a B.A. in Government from Dartmouth College.

Michael Hurley, M.D.

Michael Hurley, M.D., is a Principal on the Medical Technologies team and joined the Firm in 2022. Prior to Deerfield, Dr. Hurley was a Senior Associate at Blackstone Life Sciences where he focused on investments across medtech, biotech, and pharma. Before Blackstone, he served as an Assistant Clinical Professor at the University of California San Francisco (UCSF) and was a practicing physician at the San Francisco Veterans Affairs Medical Center. He completed his residency at UCSF and is board certified in Internal Medicine. Dr. Hurley holds a B.S. in Materials Science and Engineering from the Massachusetts Institute of Technology and an M.S. in Clinical Epidemiology and Biostatistics and an M.D. from Stanford University School of Medicine.

Michael Bergen

Michael Bergen is a Principal on the Medical Technologies team and joined the Firm in 2022. Prior to Deerfield, Mr. Bergen was a Senior Research Analyst for Millennium Partners for almost three years. He has also held roles at Point 72 for a combined seven years, most recently as Senior Research Analyst, and Apax Partners for over three years. Before these roles, Mr. Bergen held positions at Davidson Kempner Capital Management, J.W. Childs Associates and Citi. Mr. Bergen holds a B.A. in Engineering from Dartmouth College and an M.B.A. from the Wharton School of the University of Pennsylvania.

David Neustaedter, Ph.D.

David Neustaedter, Ph.D., is a Venture Partner on the Medical Technologies team and joined the Firm in 2022. Prior to Deerfield, Dr. Neustaedter spent seven years as a Vice President, at Medtronic Ventures and, before Medtronic’s merger with Covidien, spent a further 7 years with Covidien including five years as a Vice President of Venture Capital. He has also held positions at Stryker Development, Leerink Swann/MEDACorp Strategy Consulting, Fletcher Spaght, and Braun Consulting. Dr. Neustaedter holds a B.Sc. in Cellular, Molecular, and Microbial Biology from University of Calgary, an M.B.A  from Yale University, and a Ph.D. in Molecular Biology from University of British Columbia.

Brian Chow, Ph.D.

Brian Chow, Ph.D., is a Principal on the Therapeutics team and joined the Firm in 2022.  Prior to Deerfield, Dr. Chow spent 10 years at the University of Pennsylvania, most recently as an Associate Professor of Bioengineering. Before that, he was the Head of Research Operations and Alliances for Sage Therapeutics and a Venture Associate at Third Rock Ventures.  Dr. Chow holds a B.S. in Chemistry from Stanford University and a Ph.D. in Media Arts and Sciences from the Massachusetts Institute of Technology.

Alia Abdelhameed

Alia Abdelhameed is an Associate on the Therapeutics team. Ms. Abdelhameed joined the Firm in 2021 as a Fellow. She holds a B.E. in Biomedical Engineering with a minor in Physics from The City University of New York’s Macaulay Honors College.

Timothy Leahy

Timothy Leahy is a Partner on the Healthcare Services team and joined the Firm in 2022.  Prior to Deerfield, Mr. Leahy spent three years at Concord Health Partners as a Partner and a year at BelHealth Investment Partners as a Managing Director.  Before these roles, he spent nearly 19 years at Goldman Sachs in roles of increasing responsibility, including as a portfolio manager in Goldman Sachs Asset Management and as a healthcare analyst in Goldman’s Global Investment Research.  Mr. Leahy holds a B.S. in Business Administration from University of Richmond.